Overbrook Management Corp Bristol Myers Squibb CO Transaction History

Overbrook Management Corp

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $2,894 - $3,236	-50 Reduced 0.94%	5,290 $307,000
Q2 2023 Aug 11, 2023	SELL	$63.71 - $70.74 $25,484 - $28,295	-400 Reduced 6.97%	5,340 $341,000
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $44,377 - $51,982	-750 Reduced 11.56%	5,740 $340,000
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $1,114 - $1,213	-18 Reduced 0.28%	6,490 $434,000
Q1 2021 May 17, 2021	SELL	$59.34 - $66.74 $52,812 - $59,398	-890 Reduced 12.03%	6,508 $411,000
Q3 2020 Nov 16, 2020	SELL	$57.43 - $63.64 $24,120 - $26,728	-420 Reduced 5.37%	7,398 $446,000
Q4 2019 Feb 13, 2020	SELL	$49.21 - $64.19 $23,227 - $30,297	-472 Reduced 5.69%	7,818 $502,000
Q2 2019 Aug 13, 2019	SELL	$44.62 - $49.34 $6,693 - $7,401	-150 Reduced 1.78%	8,290 $376,000
Q1 2019 May 14, 2019	SELL	$45.12 - $53.8 $10,828 - $12,912	-240 Reduced 2.76%	8,440 $403,000
Q4 2018 Feb 12, 2019	SELL	$48.76 - $63.23 $53,636 - $69,553	-1,100 Reduced 11.25%	8,680 $451,000
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $33,114 - $37,350	-600 Reduced 5.78%	9,780 $607,000
Q2 2018 Aug 08, 2018	SELL	$50.53 - $62.98 $5,053 - $6,298	-100 Reduced 0.95%	10,380 $574,000
Q1 2018 May 14, 2018	SELL	$59.92 - $68.98 $296,604 - $341,451	-4,950 Reduced 32.08%	10,480 $663,000
Q4 2017 Feb 12, 2018	SELL	$59.94 - $65.35 $46,153 - $50,319	-770 Reduced 4.75%	15,430 $946,000
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $894,726 - $1.03 Million	16,200	16,200 $1.03 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Overbrook Management Corp, based on Form 13F filings with the SEC.

Stay updated on Overbrook Management Corp with notifications on news.